The Strategic Transition Toward Multi-Omic Integration and the Rise of "Pan-Biomarker" Profiling for Precision Oncology within the Biomarkers Sector for Early 2026
The most significant technological leap in early 2026 is the shift from single-analyte testing to integrated multi-omic profiling. Instead of looking at a single genetic mutation, clinicians are now using "pan-biomarker" panels that simultaneously analyze genomics, proteomics, and metabolomics from a single blood draw. This holistic view allows for a much deeper understanding of the "biological...
0 Комментарии 0 Поделились 46 Просмотры 0 предпросмотр
Realfrd – Build Friendships That Last https://realfrd.com